mesowatch
HomeImmunotherapy Combo Can Improve Survival Time
divider

Immunotherapy Combo Can Improve Survival Time for Relapsed Mesothelioma

Immunotherapy Combo Can Improve Survival Time for Relapsed Mesothelioma

An immunotherapy cocktail could aid relapsed mesothelioma patients without surgical options, according to a recent study.

A team of Italian researchers reported that a combination of two immunotherapy drugs improved long-term survival for patients whose mesothelioma had returned and was now inoperable.

The team — which included researchers from the University Hospital of Sienna and one from the SDN Institute in Naples — published their findings April 9 in The Lancet: Respiratory Medicine.

Follow-up Study

The open-label trial was a follow-up to earlier research published in 2018. Both Phase II studies relied on combining tremelimumab, an antibody-based drug still in clinical trials, with durvalumab, an antibody-based cancer drug that goes by the brand name Imfinzi.

Both drugs are immune checkpoint inhibitors, meaning they suppress proteins that are fooled into thinking cancer cells are healthy tissue, thereby allowing the body’s natural defenses to attack the cancer.

The follow-up study focused on 17 of the original 40 trial participants whose mesothelioma had returned and could not be surgically excised. Participants received a cocktail of the two checkpoint inhibitor drugs on a monthly basis for four months, with continued treatment of just durvalumab for an additional nine months.

Improved Odds

The researchers found that 41 percent of the participants achieved “immune-related stable disease,” meaning the patients’ drug-empowered immune systems were holding the mesothelioma at bay. Nearly a quarter of patients — 23.5 percent — survived two years following the treatment, the team reported. More than half of them — 52.9 percent — lived at least a year.

An analysis conducted after the study was over found that the mesothelioma patients whose tumors had mutated as a result of the treatment had a slightly higher overall survival rate than those whose tumor cells showed less mutation. However, the team noted that the difference was not statistically significant.

No Severe Reactions

No immune-related objective responses were seen in the 17 patients who underwent retreatment, and no severe or life-threatening adverse events were reported during the study.

Given these results, the research team concluded that “tremelimumab combined with durvalumab was associated with long-term survival in patients,” and that retreatment with the immunotherapy cocktail is safe and produces “clinically meaningful outcomes.”

Patricia Shelton

Reading Time: 1 mins

Published On: April 14, 2021

Patricia Shelton - author

Dr. Patti Shelton reviews medical information on the site for accuracy. She holds both a Doctor of Medicine degree as well as a Bachelor’s degree in neuroscience from the University of Washington in Seattle. Her work focuses on communicating scientific information to the public and helping make complex concepts understandable so that patients can make their own informed decisions. She also teaches anatomy and physiology courses at the college level.

More to Read

Section Divider

Amna Anees - November 17, 2024

CHMP Recommends Pembrolizumab and Chemo for Pleural Mesothelioma

Mini Divider
Mesowatch Logo

Mesowatch serves as an industry watchdog and advocates for patients and families affected by asbestos by providing reliable and up-to-date news stories and information on asbestos and mesothelioma.

NAVIGATE

About UsEditorial GuidelinesNewsSupport and ResourcesPrivacy PolicySitemap

CONTACT US

Email: support@mesowatch.com

Phone: (866) 402-1000

Address: 3260 N Hayden Rd, Suite 210, Scottsdale, AZ 85251

Copyright © 2024 by Mesowatch. All Rights Reserved.
At Mesowatch, we strive to provide helpful information for your journey. Please remember that the content on our website is for informational purposes only and is protected by copyright law. It is not a substitute for professional medical or legal advice. We encourage you to consult qualified professionals for any health or legal concerns. Disclaimer